Related Experiment Video
Updated: Mar 11, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Inhalable Ipratropium Bromide Particle Engineering with Multicriteria Optimization
Bhavani Prasad Vinjamuri1,2, Rahul V Haware1, William C Stagner3
1College of Pharmacy & Health Sciences, Department of Pharmaceutical Sciences, Campbell University, Buies Creek, North Carolina, USA.
Abstract:
Spray-dried ipratropium bromide (IPB) microspheres for oral inhalation were engineered using Quality by Design. The interrogation of material properties, process parameters, and critical product quality attributes interplay enabled rational product design. A 27-3 screening design exhibited the Maillard reaction between L-leucine (LL) and lactose at studied outlet temperatures (OT) >130°C. A response surface custom design was used in conjunction with multicriteria optimization to determine the operating design space to achieve inhalable microparticles. Statistically significant predictive models were developed for volume median diameter (p = 0.0001, adjusted R 2 = 0.9938), span (p = 0.0278, adjusted R 2 = 0.7912), yield (p = 0.0020, adjusted R 2 = 0.9320), and OT (p = 0.0082, adjusted R 2 = 0.8768). An independent verification batch confirmed the model's predictive capability. The prediction and actual values were in good agreement. Particle size and span were 3.32 ± 0.09 μm and 1.71 ± 0.18, which were 4.7 and 5.3% higher than the predicted values. The process yield was 50.3%, compared to the predicted value of 65.3%. The OT was 100°C versus the predicted value of 105°C. The label strength of IPB microparticles was 99.0 to 105.9% w/w suggesting that enrichment occurred during the spray-drying process. The present study can be utilized to initiate the design of the first commercial IPB dry powder inhaler.
More Related Videos
Related Concept Videos
Inhaled Medications
Cholinergic Antagonists: Pharmacokinetics
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
COPD: Management Using Bronchodilators and Corticosteroids
Application of Integration: Problem Solving

